Half-year report · Q2
3353.TEDINET S100WUVY
Period2025-03-01 → 2025-08-31
Filed2025-10-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥26.9bn | 2025-03-01 → 2025-08-31 | Cons. | Net sales |
| Revenue | ¥48.4bn | 2024-03-01 → 2025-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥22.7bn | 2024-03-01 → 2024-08-31 | Cons. | Net sales |
| Operating income | ¥744m | 2025-03-01 → 2025-08-31 | Cons. | Operating income |
| Operating income | ¥828m | 2024-03-01 → 2024-08-31 | Cons. | Operating income |
| Ordinary income | ¥880m | 2025-03-01 → 2025-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2024-03-01 → 2025-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥853m | 2024-03-01 → 2024-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥1.0bn | 2025-03-01 → 2025-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥1.1bn | 2024-03-01 → 2024-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥667m | 2025-03-01 → 2025-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥710m | 2024-03-01 → 2024-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥691m | 2025-03-01 → 2025-08-31 | Cons. | Profit loss |
| Net income | ¥728m | 2024-03-01 → 2024-08-31 | Cons. | Profit loss |
| Total assets | ¥37.9bn | at 2025-08-31 | Cons. | Assets |
| Total assets | ¥34.2bn | at 2025-02-28 | Cons. | Assets |
| Total assets | ¥33.1bn | at 2024-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥22.6bn | at 2025-08-31 | Cons. | Liabilities |
| Total liabilities | ¥19.5bn | at 2025-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥15.3bn | at 2025-08-31 | Cons. | Net assets |
| Net assets / equity | ¥14.7bn | at 2025-02-28 | Cons. | Net assets |
| Net assets / equity | ¥14.4bn | at 2024-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.6bn | at 2025-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.8bn | at 2025-02-28 | Cons. | Cash and deposits |
| Cash & equivalents | ¥8.1bn | at 2025-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.6bn | at 2025-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.1bn | at 2024-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.6bn | at 2024-02-29v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2025-03-01 → 2025-08-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.2bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.5bn | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥987m | 2025-03-01 → 2025-08-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥675m | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.0bn | 2025-03-01 → 2025-08-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.0bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥354m | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥177.23 | 2025-03-01 → 2025-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥301.35 | 2024-03-01 → 2025-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥188.75 | 2024-03-01 → 2024-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 38.6% | at 2025-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.2% | at 2025-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.6% | at 2024-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-03-01 → 2025-08-31 | −¥561m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-03-01 → 2025-08-31 | −¥561m |
| Reconciling Itemsreconciling | segment profit | 2025-03-01 → 2025-08-31 | −¥94m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2025-03-01 → 2025-08-31 | ¥13.1bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2025-03-01 → 2025-08-31 | ¥13.1bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2025-03-01 → 2025-08-31 | ¥658m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2025-03-01 → 2025-08-31 | ¥4.4bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2025-03-01 → 2025-08-31 | ¥4.4bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2025-03-01 → 2025-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2025-03-01 → 2025-08-31 | ¥14m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2025-03-01 → 2025-08-31 | ¥9.9bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2025-03-01 → 2025-08-31 | ¥9.4bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2025-03-01 → 2025-08-31 | ¥555m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2025-03-01 → 2025-08-31 | ¥90m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2025-03-01 → 2025-08-31 | ¥126m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2025-03-01 → 2025-08-31 | ¥120m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2025-03-01 → 2025-08-31 | ¥5m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2025-03-01 → 2025-08-31 | ¥75m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-03-01 → 2025-08-31 | ¥27.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-03-01 → 2025-08-31 | ¥26.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-03-01 → 2025-08-31 | ¥561m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-03-01 → 2025-08-31 | ¥837m |
| Reconciling Itemsreconciling | revenue | 2024-03-01 → 2024-08-31 | −¥401m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-03-01 → 2024-08-31 | −¥401m |
| Reconciling Itemsreconciling | segment profit | 2024-03-01 → 2024-08-31 | −¥110m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥551m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥4.0bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥4.0bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥128m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥7.1bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥6.7bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥399m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥194m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥93m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥91m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥2m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥65m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-03-01 → 2024-08-31 | ¥23.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-03-01 → 2024-08-31 | ¥22.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥401m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-03-01 → 2024-08-31 | ¥938m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 529
| Item | Context | Value | Unit |
|---|---|---|---|
| Long term loans payable | CurrentQuarterInstant | 7416528000 | JPY |
| Lease obligations ncl | Prior1YearInstant | 175552000 | JPY |
| Lease obligations ncl | CurrentQuarterInstant | 162656000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 1100344000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 1170926000 | JPY |
| Other ncl | Prior1YearInstant | 522634000 | JPY |
| Other ncl | CurrentQuarterInstant | 790940000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 7850975000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 9691052000 | JPY |
| Liabilities | Prior1YearInstant | 19519641000 | JPY |
| Liabilities | CurrentQuarterInstant | 22638729000 | JPY |
| Capital stock | Prior1YearInstant | 917000000 | JPY |
| Capital stock | CurrentQuarterInstant | 917000000 | JPY |
| Capital surplus | Prior1YearInstant | 1085044000 | JPY |
| Capital surplus | CurrentQuarterInstant | 1064347000 | JPY |
| Retained earnings | Prior1YearInstant | 12391773000 | JPY |
| Retained earnings | CurrentQuarterInstant | 12414837000 | JPY |
| Treasury stock | Prior1YearInstant | -531724000 | JPY |
| Treasury stock | CurrentQuarterInstant | -7129000 | JPY |
| Shareholders equity | Prior1YearInstant | 13862094000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 14389056000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 232084000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 245703000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 3682000 | JPY |
| Remeasurements of defined benefit plans | CurrentQuarterInstant | 1841000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 235766000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | 247544000 | JPY |
| Non controlling interests | Prior1YearInstant | 614273000 | JPY |
| Non controlling interests | CurrentQuarterInstant | 638714000 | JPY |
| Net assets | Prior1YearInstant | 14712134000 | JPY |
| Net assets | CurrentQuarterInstant | 15275315000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 34231775000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 37914044000 | JPY |
| Net sales | Prior1YTDDuration | 22665446000 | JPY |
| Net sales | CurrentYTDDuration | 26935485000 | JPY |
| Cost of sales | Prior1YTDDuration | 19928084000 | JPY |
| Cost of sales | CurrentYTDDuration | 23818260000 | JPY |
| Gross profit | Prior1YTDDuration | 2737361000 | JPY |
| Gross profit | CurrentYTDDuration | 3117225000 | JPY |
| Selling general and administrative expenses | Prior1YTDDuration | 1909045000 | JPY |
| Selling general and administrative expenses | CurrentYTDDuration | 2373603000 | JPY |
| Operating income | Prior1YTDDuration | 828316000 | JPY |
| Operating income | CurrentYTDDuration | 743622000 | JPY |
| Interest income noi | Prior1YTDDuration | 2282000 | JPY |
| Interest income noi | CurrentYTDDuration | 7267000 | JPY |
| Dividends income noi | Prior1YTDDuration | 34986000 | JPY |
| Dividends income noi | CurrentYTDDuration | 47344000 | JPY |
| Subsidy income noi bounty | Prior1YTDDuration | 19157000 | JPY |
| Subsidy income noi bounty | CurrentYTDDuration | 109041000 | JPY |
| Other noi | Prior1YTDDuration | 22345000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |